ML Strategies: 340B Discount Drug Program Guidance Submitted To OMB

M
Mintz

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
Earlier this week, ML Strategies (MLS) posted its weekly Health Care Update.
United States Food, Drugs, Healthcare, Life Sciences

Earlier this week, ML Strategies (MLS) posted its weekly Health Care Update. This publication provides timely information on implementation of the Affordable Care Act, Congressional initiatives affecting the health care industry, and federal and state health regulatory developments.

In its most recent edition, MLS highlights the submission of 340B discount drug program guidance to the Office of Management and Budget for review. This guidance has been highly anticipated since a number of legal challenges in 2014 called into question the authority of the Health Resources and Services Administration to oversee certain aspects this program.

Among a number of other topics, MLS also discusses the HHS Office of the National Coordinator for Health Information Techology's release of a revised version 2.0 of their Guide to Privacy and Security of Electronic Health Information, as well as CMS's finding that the Pioneer ACO program saved $348 million over two years.

Past Health Care Updates are available here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More